Contusugene ladenovec - Gendux/Introgen

Drug Profile

Contusugene ladenovec - Gendux/Introgen

Alternative Names: Ad-p53; Ad5CMV-p53; Adenoviral p53; ADVEXIN; Contusugene ladenovec Gendux; INGN 201; RPR/INGN 201

Latest Information Update: 05 Nov 2009

Price : $50

At a glance

  • Originator Gendux; Introgen Therapeutics
  • Developer Gendux; Introgen Therapeutics; National Cancer Institute (USA)
  • Class Antineoplastics; Gene therapies
  • Mechanism of Action Tumour suppressor protein p53 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Head and neck cancer; Li-Fraumeni syndrome
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Head and neck cancer

Highest Development Phases

  • Discontinued Bladder cancer; Breast cancer; Bronchiolo-alveolar adenocarcinoma; Glioblastoma; Head and neck cancer; Li-Fraumeni syndrome; Non-small cell lung cancer; Oesophageal cancer; Orofacial cancer; Ovarian cancer; Prostate cancer

Most Recent Events

  • 05 Nov 2009 Discontinued - Phase-I for Prostate cancer in USA (Intratumoural)
  • 05 Nov 2009 Discontinued - Phase-I for Ovarian cancer in USA (Intraperitoneal)
  • 05 Nov 2009 Discontinued - Phase-I for Orofacial cancer in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top